Achieve Life Sciences (ACHV) Misses Q2 EPS by 27c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. SBUX
9. SNDK
10. MA

Go back to Achieve Life Sciences (ACHV) Misses Q2 EPS by 27c

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

August 11, 2022 4:05 PM EDT

SEATTLE and VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022 financial results and provided an update on the cytisinicline clinical development program.

Recent Events & Highlights

Reported statistically significant results from the Phase 3 ORCA-2 clinical trial of cytisinicline in 810 adult smokersAwarded $2.5 million grant from the National Institutes of Health (NIH) to conduct ORCA-V1 Phase 2 trial of cytisinicline in... More